Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China.
Department of Clinical Laboratory, Wuhan Jinyintan Hospital, Wuhan 430000, China.
Int Immunopharmacol. 2020 Dec;89(Pt A):107065. doi: 10.1016/j.intimp.2020.107065. Epub 2020 Oct 3.
Patients with severe coronavirus disease 2019 (COVID-19) develop acute respiratory distress and multi-system organ failure and are associated with poor prognosis and high mortality. Thus, there is an urgent need to identify early diagnostic and prognostic biomarkers to determine the risk of developing serious illness.
We retrospectively analyzed 114 patients with COVID-19 at the Jinyintan Hospital, Wuhan based on their clinical and laboratory data. Patients were categorized into severe and mild to moderate disease groups. We analyzed the potential of serological inflammation indicators in predicting the severity of COVID-19 in patients using univariate and multivariate logistic regression, receiver operating characteristic curves, and nomogram analysis. The Spearman method was used to understand the correlation between the serological biomarkers and duration of hospital stay.
Patients with severe disease had reduced neutrophils and lymphocytes; severe coagulation dysfunction; altered content of biochemical factors (such as urea, lactate dehydrogenase); elevated high sensitivity C-reactive protein levels, neutrophil-lymphocyte, platelet-lymphocyte, and derived neutrophil-lymphocyte ratios, high sensitivity C-reactive protein-prealbumin ratio (HsCPAR), systemic immune-inflammation index, and high sensitivity C-reactive protein-albumin ratio (HsCAR); and low lymphocyte-monocyte ratio, prognostic nutritional index (PNI), and albumin-to-fibrinogen ratio. PNI, HsCAR, and HsCPAR correlated with the risk of severe disease. The nomogram combining the three parameters showed good discrimination with a C-index of 0.873 and reliable calibration. Moreover, HsCAR and HsCPAR correlated with duration of hospital stay.
Taken together, PNI, HsCAR, and HsCPAR may serve as accurate biomarkers for the prediction of disease severity in patients with COVID-19 upon admission/hospitalization.
患有严重 2019 年冠状病毒病(COVID-19)的患者会出现急性呼吸窘迫和多系统器官衰竭,并伴有不良预后和高死亡率。因此,迫切需要识别早期诊断和预后生物标志物,以确定发生严重疾病的风险。
我们根据临床和实验室数据,对武汉金银潭医院的 114 例 COVID-19 患者进行了回顾性分析。患者分为重症和轻症/中度疾病组。我们使用单变量和多变量逻辑回归、受试者工作特征曲线和列线图分析,分析了血清炎症指标预测 COVID-19 患者严重程度的潜力。使用 Spearman 方法了解血清生物标志物与住院时间之间的相关性。
重症患者的中性粒细胞和淋巴细胞减少;严重的凝血功能障碍;生化因子(如尿素、乳酸脱氢酶)含量改变;高敏 C 反应蛋白水平、中性粒细胞-淋巴细胞、血小板-淋巴细胞和衍生中性粒细胞-淋巴细胞比值、高敏 C 反应蛋白-前白蛋白比值(HsCPAR)、全身免疫炎症指数和高敏 C 反应蛋白-白蛋白比值(HsCAR)升高;淋巴细胞-单核细胞比值、预后营养指数(PNI)和白蛋白-纤维蛋白原比值降低。PNI、HsCAR 和 HsCPAR 与发生重症的风险相关。结合这三个参数的列线图具有良好的区分度,C 指数为 0.873,且校准可靠。此外,HsCAR 和 HsCPAR 与住院时间相关。
综上所述,PNI、HsCAR 和 HsCPAR 可能成为 COVID-19 患者入院/住院时疾病严重程度的准确生物标志物。